40 Chapter 3 Table 1. Characteristics of all 33 eligible patients in relation to tumour type. (continued) Tumour type Total AdC (n=19) SqCC (n=12) NOS (n=2) 33 Stage IA/B 4 1 1 6 IIA/B 12 9 1 22 IIIA/B 2 2 0 4 IV 1 0 0 1 MIB1 <20% 11 2 2 15 20-50% 7 7 0 14 >50% 1 3 0 4 PDL-1 <1% 17 6 1 24 1-50% 1 3 1 5 >50% 1 3 0 4 AdC adenocarcinoma, SqCC squamous cell carcinoma, NOS not otherwise specified Immunohistochemistry Low proliferative activity (<20% MIB-1) was associated with better OS (p=0.016): 2-year OS of 73% compared to 43% and 25%, respectively for moderate (MIB-1 20-50%) and high proliferative activity (MIB-1 >50%). A cut-off point of <20% MIB-1 revealed a significant difference for OS as well as DFS: p= 0.016 and <0.001, respectively (table 2 and figure 1). In 24/33 of patients (73%), the number of PD-L1 positive cells was less than 1%. Of these 24 patients, 16 (66.7%) died of their disease, compared to 3 of the 5 patients (80%) with PD-L1 score of 1-50% and all 4 (100%) of those with a PD-L1 score >50% (OS p=0.021; DFS p=0.066) (figure 2). Table 2. The distribution of Mib-1 scores in the 33 resection specimen cases, related to 2-years overall survival (OS) and progression free survival (PFS) OS p-value PFS p-value 2-years 95% CI 2-years 95% CI MIB-1 <20% 73% 51-96% 0.016 50% 24-76% <0.001 20-50% 43% 17-69% 23% 0-46% >50% 25% 0-67% 0% NE NE not estimated; OS overall survival; PFS progression-free survival
RkJQdWJsaXNoZXIy MTk4NDMw